The use of recombinant human TFPI (rhTFPI) in a murine APL model significantly decreased thrombin–antithrombin complexes and led to a stabilization of the APL-driven coagulopathy [88]. The gene discussed is TFPI; the disease is acute promyelocytic leukemia.